Mink Therapeutics (INKT) Stock
Early stage biotech developing cell based cancer treatments. Here's the price, business snapshot, and what's worth knowing about Mink Therapeutics in October 2026.
Mink Therapeutics, Inc. (INKT) is a small‑capitalisation biotechnology company (market cap about $67m) focused on developing cell‑based immunotherapies and related immune‑oncology approaches. Investors should know it is an early‑stage, research‑driven business: valuation tends to reflect scientific progress, clinical or preclinical milestones, partnerships and the ability to raise capital rather than steady revenues. That profile creates potential upside if programmes advance, but also significant downside from trial setbacks, regulatory hurdles, manufacturing complexity and financing risk. Shares can be highly volatile and subject to dilution from future fundraising. This summary is educational only and not personal investment advice; it is intended to help you understand the company’s business and risks. Suitable investors are typically those comfortable with long time horizons, high uncertainty and the possibility of loss. Always consider seeking independent financial advice before investing.
Mink Therapeutics (INKT) Stock Forecast
Analyst price target, next 12 months
$23.50
+88.9% vs today's $12.44
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Mink Therapeutics have a consensus 12-month target of $23.50, above the current price of $12.44.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying MINK Therapeutics' stock, with a target price indicating strong growth potential.
Financial Health
Mink Therapeutics is generating solid cash flow, indicating good financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Cell therapy focus
Develops cell‑based immunotherapies and immune approaches; scientific progress can influence value, though clinical outcomes remain uncertain.
Early-stage potential
Small market cap can offer upside if milestones succeed, but shares are often volatile and future fundraising may dilute holders.
Regulatory pathway matters
Advancement depends on trial results and approvals across jurisdictions; commercialisation requires capital, manufacturing and partnerships.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.